Congress has a packed calendar before the midterm elections, and psychedelics aren't a top priority for leadership. Even though some lawmakers support change, the people who control what gets voted on haven't pushed it forward. This means federal legalization stays off the table for at least another year.
Pre-midterm legislative calendars are historically congested with must-pass appropriations and constituent-facing bills. Psychedelic reform lacks the committee chairmanship support needed to secure floor time. Co-sponsor counts are irrelevant to scheduling — leadership controls the calendar. No major psychedelic bill has cleared committee in either chamber as of May 2026, making a floor vote in roughly five months structurally implausible.